Company Overview

International Wex Technologies Inc. (the 'Company') is a neuro- bioscience company, federally incorporated in Canada in 1992, dedicated to the discovery of medicine for the management of pain in order to minimize human suffering. The Company is a leader in the extraction, refinement and manufacture of Tetrodotoxin (TTX), a purified complex, non-protein toxin extracted from the puffer fish. The Company initially identified TTX for use in the management of pain and other symptoms associated with withdrawal from prescription and non- prescription opiates, and used the trade name Tetrodin for this indication. The Company also conducted research on the analgesic effects of TTX in order to determine the potential for the market for the management of chronic and acute pain. The trade name Tectin is used for these potential analgesic indications. In animal studies involving TTX, the potential of the drug substance for use as a local or regional anesthetic was also identified. The Company uses the trade name Tocudin for these anesthetic indications. Since the company's public listing on the Canadian Ventures Exchange in 1992 to the present, substantial capital has been directed to the research and development of various drugs, and subsequently, the protection of our intellectual knowledge by filing multiple patents. The lead products, Tetrodin and Tectin are being processed through the regulatory channels for approvals in Canada, United States and Europe, and ultimately pharmaceutical sales.

Company Information

Additional Details

Legal Name: Wex Pharmaceuticals Inc.

Number of Employees: 12

Contacts

Products

• Tectin
• Tetrodin

  A revolutionary non-narcotic pharmaceutical, with potent analgesic properties, developed from the naturally organic substance tetrodotoxin (TTX). Tetrodin, with experiments to date, has shown to provide a safe, cost effective primary withdrawal treatment solution for heroin and other opiate addiction to substances such as morphine, opium and methadone.

• Tocudin

  Targeted at the local and topical anesthetic market, for patients undergoing surgery or procedures for which general anesthesia (loss of consciousness) may be impractical or unnecessary, Tocudin is undergoing intensive preclinical testing at the world-renowned Beijing Medical University in China, where the Company's research & development and manufacturing operations are currently located, resulting to date in positive and very promising results.

NAICS Categories

• 325410 Pharmaceutical and Medicine Manufacturing

Additional Information